SCHEMBL9928463

SCHEMBL9928463

CCOC(=O)C(N1CCCC1)C(O)(c1ccccc1)c1ccccn1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
POLB P06746 1/20 0.40
KDM4E B2RXH2 2/20 0.39
CHRM3 P20309 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CHRM2 P08172 1/20 0.38
CHRM1 P11229 1/20 0.38
KCNA5 P22460 2/20 0.38
KCNH2 Q12809 2/20 0.38
NOS2 P35228 1/20 0.38
CETP P11597 3/20 0.37
ABHD6 Q9BV23 1/20 0.37
DAGLA Q9Y4D2 1/20 0.37
BLM P54132 1/20 0.36
CYP2D6 P10635 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1242086 0.87 KCNA5 (0.43) MEN1KMT2ACHRM3ALDH1A1GAA
SCHEMBL1243557 0.73 KCNA5 (0.64) MEN1KMT2APOLBCHRM3SMN1; SMN2
SCHEMBL2553058 0.71 MEN1 (0.54) MEN1KMT2AKDM4ECHRM3ALDH1A1
SCHEMBL1243308 0.69 KCNA5 (0.48) MEN1KMT2ACHRM3ALDH1A1SMN1; SMN2
SCHEMBL16132367 0.68 SMN1; SMN2 (0.52) MEN1KMT2ACHRM3ALDH1A1SMN1; SMN2
SCHEMBL11760691 0.67 SMN1; SMN2 (0.48) MEN1KMT2AKDM4EALDH1A1GAA
SCHEMBL6562845 0.66 PIN1 (0.47) MEN1KMT2APOLBALDH1A1SMN1; SMN2
SCHEMBL6561186 0.66 PIN1 (0.47) MEN1KMT2APOLBALDH1A1SMN1; SMN2
SCHEMBL6207625 0.66 KCNA5 (0.45) MEN1KMT2AKDM4ECHRM3ALDH1A1
SCHEMBL2550556 0.66 LMNA (0.68) MEN1KMT2AKDM4ECHRM3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1781635-B1 POTASSIUM CHANNEL INHIBITORS MERCK SHARP & DOHME (US) 2012-06-13 EP disclosed
US-7879839-B2 For treatment and prevention of cardiac arrhythmias; (+-)-2-Morpholin-4-yl-2-phenyl-1,1-dipyridin-3-yl-ethanol; (+-)-2-[(2-methoxyethyl)(methyl)amino]-2-phenyl-1,1-dipyridin-3-ylethanol MERCK SHARP & DOHME CORP. (US) 2011-02-01 US disclosed
US-7879839-B2 For treatment and prevention of cardiac arrhythmias; (+-)-2-Morpholin-4-yl-2-phenyl-1,1-dipyridin-3-yl-ethanol; (+-)-2-[(2-methoxyethyl)(methyl)amino]-2-phenyl-1,1-dipyridin-3-ylethanol MERCK SHARP & DOHME CORP. (US) 2011-02-01 US disclosed
US-20080090794-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME LLC 2008-04-17 US disclosed
US-20080090794-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME LLC 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090794-A1 Potassium Channel Inhibitors KCNJ2, KCNQ2, KCNH2 MEN1 2152/4885KMT2A 278/4885POLB 4819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.